Ticagrelor Monotherapy vs Ticagrelor With Aspirin and Adverse Events in Acute Coronary Syndrome | Acute Coronary Syndromes | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary SyndromeThe TICO Randomized Clinical Trial

Educational Objective
To understand the risks and benefits of dual antiplatelet therapy.
1 Credit CME
Key Points

Question  Does switching to ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduce net adverse clinical events (a composite of major bleeding and major adverse cardiac and cerebrovascular events) among patients with acute coronary syndrome treated with drug-eluting stents?

Findings  In this randomized clinical trial that included 3056 patients with acute coronary syndrome, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor-based 12-month dual antiplatelet therapy, significantly reduced net adverse clinical events at 1 year (3.9% vs 5.9%).

Meaning  Among patients with acute coronary syndrome treated with new-generation drug-eluting stents, use of ticagrelor monotherapy after 3 months of dual antiplatelet therapy resulted in a modest but statistically significant reduction in a composite outcome of major bleeding and adverse cardiac and cerebrovascular events at 1 year.

Abstract

Importance  Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).

Objective  To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents.

Design, Setting, and Participants  A randomized multicenter trial was conducted in 3056 patients with ACS treated with drug-eluting stents between August 2015 and October 2018 at 38 centers in South Korea. Follow-up was completed in October 2019.

Interventions  Patients were randomized to receive ticagrelor monotherapy (90 mg twice daily) after 3-month DAPT (n = 1527) or ticagrelor-based 12-month DAPT (n = 1529).

Main Outcomes and Measures  The primary outcome was a 1-year net adverse clinical event, defined as a composite of major bleeding and adverse cardiac and cerebrovascular events (death, myocardial infarction, stent thrombosis, stroke, or target-vessel revascularization). Prespecified secondary outcomes included major bleeding and major adverse cardiac and cerebrovascular events.

Results  Among 3056 patients who were randomized (mean age, 61 years; 628 women [20%]; 36% ST-elevation myocardial infarction), 2978 patients (97.4%) completed the trial. The primary outcome occurred in 59 patients (3.9%) receiving ticagrelor monotherapy after 3-month DAPT and in 89 patients (5.9%) receiving ticagrelor-based 12-month DAPT (absolute difference, −1.98% [95% CI, −3.50% to −0.45%]; hazard ratio [HR], 0.66 [95% CI, 0.48 to 0.92]; P = .01). Of 10 prespecified secondary outcomes, 8 showed no significant difference. Major bleeding occurred in 1.7% of patients with ticagrelor monotherapy after 3-month DAPT and in 3.0% of patients with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09).

Conclusions and Relevance  Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor-based 12-month dual antiplatelet therapy, resulted in a modest but statistically significant reduction in a composite outcome of major bleeding and cardiovascular events at 1 year. The study population and lower than expected event rates should be considered in interpreting the trial.

Trial Registration  ClinicalTrials.gov Identifier: NCT02494895

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Yangsoo Jang, MD, PhD, Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, South Korea (jangys1212@yuhs.ac).

Accepted for Publication: April 22, 2020.

Author Contributions: Dr Jang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs B.-K. Kim and S.-J. Hong contributed equally to this work.

Concept and design: B.-K. Kim, S.-J. Hong, Y.-H. Cho, S. Cho, Jeon, D.-K. Cho, B.-K. Hong, Ahn, Shin, Nam, J.-S. Kim, Choi, M.-K. Hong, Jang.

Acquisition, analysis, or interpretation of data: B.-K. Kim, S.-J. Hong, Y.-H. Cho, Yun, Y.-H. Kim, Suh, J.Y. Cho, Her, S. Cho, Jeon, Yoo, D.-K. Cho, B.-K. Hong, Kwon, Shin, Nam, J.-S. Kim, Ko, Choi, M.-K. Hong, Jang.

Drafting of the manuscript: B.-K. Kim, S.-J. Hong, Yun, Y.-H. Kim, Suh, J.Y. Cho, Jeon, D.-K. Cho, B.-K. Hong, Kwon, J.-S. Kim, M.-K. Hong, Jang.

Critical revision of the manuscript for important intellectual content: B.-K. Kim, S.-J. Hong, Y.-H. Cho, Suh, Her, S. Cho, Jeon, Yoo, Ahn, Shin, Nam, J.-S. Kim, Ko, Choi, M.-K. Hong, Jang.

Statistical analysis: B.-K. Kim, S.-J. Hong, Suh, Her, Jeon, Shin, Nam, J.-S. Kim, Jang.

Obtained funding: Jeon, Jang.

Administrative, technical, or material support: B.-K. Kim, S.-J. Hong, Yun, Y.-H. Kim, J.Y. Cho, Her, S. Cho, Jeon, D.-K. Cho, Kwon, Ahn, Shin, J.-S. Kim, Choi, M.-K. Hong, Jang.

Supervision: B.-K. Kim, S. Cho, Jeon, D.-K. Cho, B.-K. Hong, Kwon, J.-S. Kim, Choi, M.-K. Hong, Jang.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by the Cardiovascular Research Center, Seoul, South Korea and funded by Biotronik (Bülach, Switzerland).

Role of the Funder/Sponsor: Biotronik had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

The TICO Investigators: Yangsoo Jang, MD, Yonsei University, Severance Hospital, Seoul; Bum-Kee Hong, MD, Yonsei University, Gangnam Severance Hospital, Seoul; Seung-Hwan Lee, Wonju Christian Hospital, Wonju; Myung-Ho Yoon, Ajou University Hospital, Suwon; Jin-Bae Lee, Daegu Catholic University Medical Center, Daegu; Jung-Hee Lee, Yeungnam University Medical Center, Daegu; Woong Cheol Kang, Gachon Gil University Hospital, Incheon; Sungsoo Cho, Dankook University Hospital, Cheonan; Kyeong Ho Yun, MD, PhD, Wonkwang University Hospital, Iksan; Ki-Hwan Kwon, Ewha Womans University Mokdong Hospital, Seoul; Sang-Yong Yoo, MD, PhD, GangNeung Asan Hospital, Gangneung; Sang-Ho Park, Soonchunhyang University Hospital Cheonan, Cheonan; Jang-Hwan Bae, Chungbuk National University Hospital, Chungbuk; Jong-Pil Park, Presbyterian Medical Center, Jeonju; Doo-Il Kim, Inje University Haeundae Paik Hospital, Busan; Jung-Ho Heo, Kosin University Gospel Hospital, Busan; Yon-Hyeong Cho, Myongji Hospital, Hanyang University, Goyang; Woong-Kil Choi, Konkuk University Chungju Hospital, Chungju; Jin-Man Cho, Kyung Hee University Gandong Hospital, Gangdong; Hyun-Hee Choi, Hallym University Chuncheon Scared Hospital, Chuncheon; Yong Hoon Kim, Kangwon National University School of Medicine, Chuncheon; Seung-Ki Yoo, Seoul Eulji Hospital, Seoul; Kee-Seok Kim, Jeju National University Hostpial, Jeju; Yoon-Kyoung Cho, Keimyung University Dongsan Hospital, Daegu; Kook-Jin Chun, Pusan National University Yangsan Hospital, Yangsan; Moo-Hyun Kim, Dong-A University Hospital, Busan; Dong Woon Jeon, National Health Insurance Service Ilsan Hospital, Goyang; Eui Im, Yonsei University Yongin Severance Hospital, Yongin; Jung-Rae Cho, Hallym University Kangnam Sacred Heart Hospital, Seoul; Gwang-Soo Cha, Pusan National University Hospital, Busan; Tae-Hyun Yang, Inje University Busan Paik Hospital, Busan; Seung-Yul Lee, Wonkwang University Sanbon Hospital, Gunpo; Won Kim, Kyung Hee University Hospital, Seoul; Woo-Jung Park, Hallym University Sacred Heart Hospital, Anyang; Sang-Wook Kim, Chung-Ang University Hospital, Seoul; Hee-Yul Kim, St Mary's Hospital, The Catholic University, Bucheon; Woo-Jung Cheon, Samgsung Changwon Hospital, Changwon; Sung-Woo Kwon, Inha University Hospital, Incheon.

Data Sharing Statement: See Supplement 3.

References
1.
Levine  GN , Bates  ER , Bittl  JA ,  et al.  2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.   J Am Coll Cardiol. 2016;68(10):1082-1115. doi:10.1016/j.jacc.2016.03.513PubMedGoogle ScholarCrossref
2.
Valgimigli  M , Bueno  H , Byrne  RA ,  et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).   Eur Heart J. 2018;39(3):213-260. doi:10.1093/eurheartj/ehx419PubMedGoogle ScholarCrossref
3.
Wiviott  SD , Braunwald  E , McCabe  CH ,  et al; TRITON-TIMI 38 Investigators.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.   N Engl J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482PubMedGoogle ScholarCrossref
4.
Wallentin  L , Becker  RC , Budaj  A ,  et al; PLATO Investigators.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.   N Engl J Med. 2009;361(11):1045-1057. doi:10.1056/NEJMoa0904327PubMedGoogle ScholarCrossref
5.
Park  DW , Kwon  O , Jang  JS ,  et al; TICAKOREA Investigators.  Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial.   Circulation. 2019;140(23):1865-1877. doi:10.1161/CIRCULATIONAHA.119.041766PubMedGoogle ScholarCrossref
6.
Antman  EM , Wiviott  SD , Murphy  SA ,  et al.  Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.   J Am Coll Cardiol. 2008;51(21):2028-2033. doi:10.1016/j.jacc.2008.04.002PubMedGoogle ScholarCrossref
7.
Becker  RC , Bassand  JP , Budaj  A ,  et al.  Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.   Eur Heart J. 2011;32(23):2933-2944. doi:10.1093/eurheartj/ehr422PubMedGoogle ScholarCrossref
8.
Capodanno  D , Mehran  R , Valgimigli  M ,  et al.  Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.   Nat Rev Cardiol. 2018;15(8):480-496. doi:10.1038/s41569-018-0049-1PubMedGoogle ScholarCrossref
9.
Vranckx  P , Valgimigli  M , Jüni  P ,  et al; GLOBAL LEADERS Investigators.  Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.   Lancet. 2018;392(10151):940-949. doi:10.1016/S0140-6736(18)31858-0PubMedGoogle ScholarCrossref
10.
Mehran  R , Baber  U , Sharma  SK ,  et al.  Ticagrelor with or without aspirin in high-risk patients after PCI.   N Engl J Med. 2019;381(21):2032-2042. doi:10.1056/NEJMoa1908419PubMedGoogle ScholarCrossref
11.
Kim  C , Hong  SJ , Shin  DH ,  et al.  Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.   Am Heart J. 2019;212:45-52. doi:10.1016/j.ahj.2019.02.015PubMedGoogle ScholarCrossref
12.
Mehran  R , Rao  SV , Bhatt  DL ,  et al.  Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.   Circulation. 2011;123(23):2736-2747. doi:10.1161/CIRCULATIONAHA.110.009449PubMedGoogle ScholarCrossref
13.
Thygesen  K , Alpert  JS , Jaffe  AS ,  et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction.  Third universal definition of myocardial infarction.   Circulation. 2012;126(16):2020-2035. doi:10.1161/CIR.0b013e31826e1058PubMedGoogle ScholarCrossref
14.
Cutlip  DE , Windecker  S , Mehran  R ,  et al; Academic Research Consortium.  Clinical end points in coronary stent trials: a case for standardized definitions.   Circulation. 2007;115(17):2344-2351. doi:10.1161/CIRCULATIONAHA.106.685313PubMedGoogle ScholarCrossref
15.
Sacco  RL , Kasner  SE , Broderick  JP ,  et al; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism.  An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association.   Stroke. 2013;44(7):2064-2089. doi:10.1161/STR.0b013e318296aecaPubMedGoogle ScholarCrossref
16.
Kim  BK , Hong  MK , Shin  DH ,  et al; RESET Investigators.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).   J Am Coll Cardiol. 2012;60(15):1340-1348. doi:10.1016/j.jacc.2012.06.043PubMedGoogle ScholarCrossref
17.
Kaul  S , Diamond  GA .  Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.   Prog Cardiovasc Dis. 2007;49(4):284-299. doi:10.1016/j.pcad.2006.10.001PubMedGoogle ScholarCrossref
18.
Palmerini  T , Benedetto  U , Bacchi-Reggiani  L ,  et al.  Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.   Lancet. 2015;385(9985):2371-2382. doi:10.1016/S0140-6736(15)60263-XPubMedGoogle ScholarCrossref
19.
Feres  F , Costa  RA , Abizaid  A ,  et al; OPTIMIZE Trial Investigators.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.   JAMA. 2013;310(23):2510-2522. doi:10.1001/jama.2013.282183PubMedGoogle Scholar
20.
Hong  SJ , Shin  DH , Kim  JS ,  et al; IVUS-XPL Investigators.  6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial.   JACC Cardiovasc Interv. 2016;9(14):1438-1446. doi:10.1016/j.jcin.2016.04.036PubMedGoogle ScholarCrossref
21.
Hahn  JY , Song  YB , Oh  JH ,  et al; SMART-DATE Investigators.  6-Month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.   Lancet. 2018;391(10127):1274-1284. doi:10.1016/S0140-6736(18)30493-8PubMedGoogle ScholarCrossref
22.
De Luca  G , Damen  SA , Camaro  C ,  et al; Collaborators.  Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial).   EuroIntervention. 2019;15(11):e990-e998. doi:10.4244/EIJ-D-19-00539PubMedGoogle ScholarCrossref
23.
Kedhi  E , Fabris  E , van der Ent  M ,  et al.  Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.   BMJ. 2018;363:k3793. doi:10.1136/bmj.k3793PubMedGoogle ScholarCrossref
24.
Watanabe  H , Domei  T , Morimoto  T ,  et al; STOPDAPT-2 Investigators.  Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial.   JAMA. 2019;321(24):2414-2427. doi:10.1001/jama.2019.8145PubMedGoogle ScholarCrossref
25.
Hahn  JY , Song  YB , Oh  JH ,  et al; SMART-CHOICE Investigators.  Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial.   JAMA. 2019;321(24):2428-2437. doi:10.1001/jama.2019.8146PubMedGoogle ScholarCrossref
26.
Lee  SY , Hong  MK , Shin  DH ,  et al.  Association between duration of dual antiplatelet therapy and angiographic multivessel disease on outcomes in patients treated with newer-generation drug-eluting stents.   Circ Cardiovasc Interv. 2016;9(11):e004256. doi:10.1161/CIRCINTERVENTIONS.116.004256PubMedGoogle Scholar
27.
Kandzari  DE , Mauri  L , Koolen  JJ ,  et al; BIOFLOW V Investigators.  Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.   Lancet. 2017;390(10105):1843-1852. doi:10.1016/S0140-6736(17)32249-3PubMedGoogle ScholarCrossref
28.
Iglesias  JF , Muller  O , Heg  D ,  et al.  Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.   Lancet. 2019;394(10205):1243-1253. doi:10.1016/S0140-6736(19)31877-XPubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close